Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 16/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246943 | 0.88 | GRM2 (0.56) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL17787079 | 0.88 | GRM2 (0.49) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL16246817 | 0.85 | GRM2 (0.54) | GRM2KLKB1DGAT1 | |
| SCHEMBL17785429 | 0.85 | GRM2 (0.53) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL21954006 | 0.84 | KLKB1 (0.47) | KLKB1DGAT1 | |
| SCHEMBL18617480 | 0.84 | DGAT1 (0.59) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL18795949 | 0.84 | KLKB1 (0.67) | KLKB1 | |
| SCHEMBL1049941 | 0.84 | GAA (0.56) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL19779769 | 0.82 | GRM2 (0.55) | GRM2KLKB1DGAT1 | |
| SCHEMBL17785281 | 0.81 | GRM2 (0.50) | GRM2KLKB1DGAT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | GRM2 4390/4885KLKB1 1/4885DGAT1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.